Pay in 4 interest-free payments of $6.45 Learn more
Ships within 48 hours · Estimated delivery Nov 7 - Nov 12
We take immense pride in the quality of our products, and it's genuinely painful for our team to hear about research being compromised by something so preventable
Patients Treated With REGENXBIO's MPS II Gene Therapy RGX-121 Sustain 82% Median Reduction in CSF HS D2S6 Levels Through 1 Year September 10, 2025 According to a new data update from REGENXBIO's pivotal phase 1/2/3 CAMPSIITE clinical trial (NCT03566043) evaluating clemidsogene lanparvovec (RGX-121), an investigational adeno-associated virus (AAV) vector-based gene therapy for mucopolysaccharidosis type 2 (MPSII, also known as Hunter syndrome), 13 patients treated in the pivotal phase have shown an 82% reduction in heparan sulfate (HS) D2S6 levels in the cerebrospinal fluid (CSF) through 1 year posttreatment
Fail 37, 332336
Support whole-body healing with every inhale
21 Medicamento La L-carnitina es el componente principal del frmaco Levocarnitina
Reduced risk of health disorders (heart disease, stroke, infertility)
